Manfaat Tambahan

Manfaat Tambahan Pil KB

Selain mencegah kehamilan, Pil KB Kombinasi juga sarat manfaat tambahan lainnya bagi wanita. Ada manfaat tambahan umum dan manfaat tambahan yang dipengaruhi oleh hormon progestogen ataupun rejimen dari Pil KB itu sendiri.

Beberapa pil KB yang tersedia di Indonesia:

  • Pil KB dengan Progestogen Lebonorgestrel
  • Pil KB dengan Progestogen CPA (Cyproterone Acetate)
  • Pil KB dengan Progestogen Drospirenon

Manfaat Tambahan Pil KB Kombinasi Secara Umum

  • Menstruasi teratur.
  • Menurunkan risiko terkena kista ovarium.
  • Memberikan perlindungan terhadap risiko terkena miom setelah 5 tahun pemakaian.
  • Melindungi dari risiko kanker ovarium setelah penggunaan sedikitnya selama 6 bulan.
  • Perlindungan ini berlangsung hingga 10 tahun setelah penggunaan dihentikan.
  • Melindungi terhadap kanker endometrium/dinding rahim.
  • Melindungi terhadap risiko tumor jinak payudara.
  • Menurunkan risiko terkena penyakit radang panggul hingga 50%.
  • Menurunkan risiko terjadi perdarahan menstruasi yang berlebihan dan anemia akibat kekurangan zat besi
  • Menjaga Kepadatan Tulang

Manfaat Tambahan Pil KB dengan Progestogen CPA (Cyproterone Acetate)

  • Mengobati jerawat hingga derajat berat.

Manfaat Tambahan Pil KB 24/4 dengan Progestogen Drospirenon

  • Tidak menyebabkan fluktuasi hormon sehingga wanita terbebas dari masalah-masalah yang terkait dengan menstruasi, seperti perubahaan mood, perut begah, mudah tersinggung, dan mudah sedih.
  • Membantu menjaga kestabilan berat badan karena pengaruh estrogen.
Referensi:
  • Burkman, R. et. al. (2001). Current perspective on oral contraceptive use. Am J Obstet Gynecol. 185. S4-12.
  • Drife, J. O. (1996). The benefi t and risk of oral contraceptives today. 2nd edition. The Phartenon Publishing Group.
  • Dayal, M., Barnhart, K. (2001). Non contraceptive benefi ts and therapeutic uses of oral contraceptive pill. Seminar in Reproductive Medicine. 19(4). 295-303.
  • Golnick H, et. al. (1998(. The effi cacy of oral cyproterone acetate in combination with ethynilestradiol in acne trade of facial type. Journal of Dermatological Treatment, 9, 71-79.
  • Pearlstein, TB. et. al. (2005) Treatment of premenstrual dysphoric disorder with a new drospirenone-containing oral contraceptive formulation. Contraception. 72(6). 414-21.
  • Yonkers, Kimberly A. et. al. (2005) Effi cacy of new low-dose oral contraceptive with drospirenone in premenstrual dysphoric disorder. Obstet and Gynecol. 106. 3. 492-501.
  • Oelkers, W. et. al. (1995). Eff ects of new oral contraceptive containing an anti-mineralocorticoid progestogen, drospirenone, on the rennin-aldosterone system, body weight, blood pressure, glucose tolerance, and lipid metabolism. Journal of Clinical Endocrinology and Metabolism. 80. 1816-1821.
  • Koltun, W., Lucky, AW., et. al. Effi cacy and safety of 3mg drospirenone/20mcg ethinylestradiol oral contraceptive administered in 24/4 regimen in the treatment of acne vulgaris: a randomized, double-blind, placebo-controlled trial. Contraception. 77. 249-256.

 

Referensi:

  • Burkman, R. et. al. (2001). Current perspective on oral contraceptive use. Am J Obstet Gynecol. 185. S4-12.
  • Drife, J. O. (1996). The benefi t and risk of oral contraceptives today. 2nd edition. The Phartenon Publishing Group.
  • Dayal, M., Barnhart, K. (2001). Non contraceptive benefi ts and therapeutic uses of oral contraceptive pill. Seminar in Reproductive Medicine. 19(4). 295-303.
  • Golnick H, et. al. (1998(. The effi cacy of oral cyproterone acetate in combination with ethynilestradiol in acne trade of facial type. Journal of Dermatological Treatment, 9, 71-79.
  • Pearlstein, TB. et. al. (2005) Treatment of premenstrual dysphoric disorder with a new drospirenone-containing oral contraceptive formulation. Contraception. 72(6). 414-21.
  • Yonkers, Kimberly A. et. al. (2005) Effi cacy of new low-dose oral contraceptive with drospirenone in premenstrual dysphoric disorder. Obstet and Gynecol. 106. 3. 492-501.
  • Oelkers, W. et. al. (1995). Eff ects of new oral contraceptive containing an anti-mineralocorticoid progestogen, drospirenone, on the rennin-aldosterone system, body weight, blood pressure, glucose tolerance, and lipid metabolism. Journal of Clinical Endocrinology and Metabolism. 80. 1816-1821.
  • Koltun, W., Lucky, AW., et. al. Effi cacy and safety of 3mg drospirenone/20mcg ethinylestradiol oral contraceptive administered in 24/4 regimen in the treatment of acne vulgaris: a randomized, double-blind, placebo-controlled trial. Contraception. 77. 249-256.